✦ LIBER ✦

G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

✍ Scribed by J. O'Shaughnessy; C. Osborne; J. Pippen; M. Yoffe; D. Patt; G. Monaghan; C. Rocha; V. Ossovskaya; B. Sherman; C. Bradley

Book ID: 119600782
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)72040-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase 1 trial of the poly(ADP-ribose)

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

✍ Liu, Joyce F.; Tolaney, Sara M.; Birrer, Michael; Fleming, Gini F.; Buss, Mary K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 580 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB